Cargando…

The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study

BACKGROUND: Despite its biologic plausibility, the association between liver function and mortality of patients with chronic liver disease is not well supported by data. Therefore, we examined whether the galactose elimination capacity (GEC), a physiological measure of the total metabolic capacity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jepsen, Peter, Vilstrup, Hendrik, Ott, Peter, Keiding, Susanne, Andersen, Per K, Tygstrup, Niels
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721849/
https://www.ncbi.nlm.nih.gov/pubmed/19566919
http://dx.doi.org/10.1186/1471-230X-9-50
_version_ 1782170242098659328
author Jepsen, Peter
Vilstrup, Hendrik
Ott, Peter
Keiding, Susanne
Andersen, Per K
Tygstrup, Niels
author_facet Jepsen, Peter
Vilstrup, Hendrik
Ott, Peter
Keiding, Susanne
Andersen, Per K
Tygstrup, Niels
author_sort Jepsen, Peter
collection PubMed
description BACKGROUND: Despite its biologic plausibility, the association between liver function and mortality of patients with chronic liver disease is not well supported by data. Therefore, we examined whether the galactose elimination capacity (GEC), a physiological measure of the total metabolic capacity of the liver, was associated with mortality in a large cohort of patients with newly-diagnosed cirrhosis. METHODS: By combining data from a GEC database with data from healthcare registries we identified cirrhosis patients with a GEC test at the time of cirrhosis diagnosis in 1992–2005. We divided the patients into 10 equal-sized groups according to GEC and calculated all-cause mortality as well as cirrhosis-related and not cirrhosis-related mortality for each group. Cox regression was used to adjust the association between GEC and all-cause mortality for confounding by age, gender and comorbidity, measured by the Charlson comorbidity index. RESULTS: We included 781 patients, and 454 (58%) of them died during 2,617 years of follow-up. Among the 75% of patients with a decreased GEC (<1.75 mmol/min), GEC was a strong predictor of 30-day, 1-year, and 5-year mortality, and this could not be explained by confounding (crude hazard ratio for a 0.5 mmol/min GEC increase = 0.74, 95% CI 0.59–0.92; adjusted hazard ratio = 0.64, 95% CI 0.51–0.81). Further analyses showed that the association between GEC and mortality was identical for patients with alcoholic or non-alcoholic cirrhosis etiology, that it also existed among patients with comorbidity, and that GEC was only a predictor of cirrhosis-related mortality. Among the 25% of patients with a GEC in the normal range (≥ 1.75 mmol/min), GEC was only weakly associated with mortality (crude hazard ratio = 0.79, 95% CI 0.59–1.05; adjusted hazard ratio = 0.80, 95% CI 0.60–1.08). CONCLUSION: Among patients with newly-diagnosed cirrhosis and a decreased GEC, the GEC was a strong predictor of short- and long-term all-cause and cirrhosis-related mortality. These findings support the expectation that loss of liver function increases mortality.
format Text
id pubmed-2721849
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27218492009-08-06 The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study Jepsen, Peter Vilstrup, Hendrik Ott, Peter Keiding, Susanne Andersen, Per K Tygstrup, Niels BMC Gastroenterol Research Article BACKGROUND: Despite its biologic plausibility, the association between liver function and mortality of patients with chronic liver disease is not well supported by data. Therefore, we examined whether the galactose elimination capacity (GEC), a physiological measure of the total metabolic capacity of the liver, was associated with mortality in a large cohort of patients with newly-diagnosed cirrhosis. METHODS: By combining data from a GEC database with data from healthcare registries we identified cirrhosis patients with a GEC test at the time of cirrhosis diagnosis in 1992–2005. We divided the patients into 10 equal-sized groups according to GEC and calculated all-cause mortality as well as cirrhosis-related and not cirrhosis-related mortality for each group. Cox regression was used to adjust the association between GEC and all-cause mortality for confounding by age, gender and comorbidity, measured by the Charlson comorbidity index. RESULTS: We included 781 patients, and 454 (58%) of them died during 2,617 years of follow-up. Among the 75% of patients with a decreased GEC (<1.75 mmol/min), GEC was a strong predictor of 30-day, 1-year, and 5-year mortality, and this could not be explained by confounding (crude hazard ratio for a 0.5 mmol/min GEC increase = 0.74, 95% CI 0.59–0.92; adjusted hazard ratio = 0.64, 95% CI 0.51–0.81). Further analyses showed that the association between GEC and mortality was identical for patients with alcoholic or non-alcoholic cirrhosis etiology, that it also existed among patients with comorbidity, and that GEC was only a predictor of cirrhosis-related mortality. Among the 25% of patients with a GEC in the normal range (≥ 1.75 mmol/min), GEC was only weakly associated with mortality (crude hazard ratio = 0.79, 95% CI 0.59–1.05; adjusted hazard ratio = 0.80, 95% CI 0.60–1.08). CONCLUSION: Among patients with newly-diagnosed cirrhosis and a decreased GEC, the GEC was a strong predictor of short- and long-term all-cause and cirrhosis-related mortality. These findings support the expectation that loss of liver function increases mortality. BioMed Central 2009-06-30 /pmc/articles/PMC2721849/ /pubmed/19566919 http://dx.doi.org/10.1186/1471-230X-9-50 Text en Copyright ©2009 Jepsen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jepsen, Peter
Vilstrup, Hendrik
Ott, Peter
Keiding, Susanne
Andersen, Per K
Tygstrup, Niels
The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title_full The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title_fullStr The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title_full_unstemmed The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title_short The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study
title_sort galactose elimination capacity and mortality in 781 danish patients with newly-diagnosed liver cirrhosis: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721849/
https://www.ncbi.nlm.nih.gov/pubmed/19566919
http://dx.doi.org/10.1186/1471-230X-9-50
work_keys_str_mv AT jepsenpeter thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT vilstruphendrik thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT ottpeter thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT keidingsusanne thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT andersenperk thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT tygstrupniels thegalactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT jepsenpeter galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT vilstruphendrik galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT ottpeter galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT keidingsusanne galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT andersenperk galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy
AT tygstrupniels galactoseeliminationcapacityandmortalityin781danishpatientswithnewlydiagnosedlivercirrhosisacohortstudy